Highnoon Laboratories Limited has reported a steady financial performance for the six months ended June 30, 2026, with revenue and profitability showing year-on-year improvement.
According to the company’s financial results, revenue from contracts with customers increased to Rs12.71 billion during the first half of 2026, compared with Rs12.04 billion in the same period of 2025. The increase reflects continued growth in the company’s business despite higher operating costs.
The company’s profit after tax rose to Rs1.68 billion, up from approximately Rs1.63 billion a year earlier. This represents an increase of around 3% and indicates that Highnoon was able to translate higher revenue into improved bottom-line earnings.
Earnings per share also edged higher, reaching Rs31.66 for the six-month period, compared with Rs30.71 in the corresponding period of 2025. The improvement in EPS provides another indication of the company’s relatively stable earnings performance.
Stronger quarterly performance
Looking specifically at the three months ended June 30, 2026, Highnoon Laboratories recorded profit after tax of Rs721.8 million, compared with Rs711.7 million in the same quarter last year. However, quarterly earnings per share stood at Rs13.87, compared with Rs14.74 previously, reflecting changes in the company’s quarterly earnings profile.
The company also reported an increase in profit from operations during the six-month period. This suggests that the underlying business continued to generate healthy operating returns, although expenses remained an important factor affecting overall profitability.
Asset base remains substantial
Highnoon Laboratories maintained a sizeable asset base during the period. Total assets stood at approximately Rs17.15 billion in the six-month financial statements, with inventories, trade receivables, cash balances and property and equipment forming important components of the balance sheet.
The company continued to invest in its operations, with capital expenditure on property and equipment recorded during the period. Its cash-flow statement also shows that the business generated positive cash from operating activities, supporting its ongoing operational and investment requirements.
Positive operating cash generation
Cash generation remains an important strength in Highnoon Laboratories’ financial position. The company generated approximately Rs2.38 billion in net cash from operating activities during the first six months of 2026, compared with about Rs598 million in the same period of 2025.
The significant improvement in operating cash flow provides the company with greater financial flexibility to meet working-capital needs and fund investments in its business.
At the same time, the company’s cash and cash equivalents stood at approximately Rs448.6 million at June 30, 2026, according to the balance sheet.
No dividend announced
Despite the improvement in earnings, the company’s announcement did not declare a cash dividend, bonus shares or right shares for the period. The official announcement also stated that there was no other entitlement or corporate action and no price-sensitive information to report.
Outlook
Highnoon Laboratories’ first-half results point to a business that continues to expand while maintaining profitability. Revenue growth, a modest increase in profit after tax and a substantial improvement in operating cash generation are among the key highlights of the financial results.
Going forward, the company’s ability to manage distribution, selling and administrative expenses while sustaining revenue growth will remain important for maintaining momentum in profitability.
Overall, Highnoon Laboratories enters the second half of 2026 with a solid financial base, positive operating cash generation and continued earnings growth. The results suggest that the pharmaceutical company remains focused on strengthening its operations while navigating the cost pressures that continue to affect the business environment.
